OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 TrialB.C. Cho,D.R. Camidge,J.J. Lin,S.-W. Kim,B. Solomon,R. Dziadziuszko,B. Besse,K. Goto,A.J. de Langen,J. Wolf, K.H. Lee,S. Popat,C. Springfeld, M. Nagasaka,E. Felip,N. Yang,S. Lu,S. Kao,V. Velcheti,P. CheemaJournal of Thoracic Oncology（2023）引用 1|浏览3暂无评分关键词repotrectinib,nsclc,fusion-positiveAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
